Seagen®

SGN-BB228

An investigational costimulatory bispecific molecule composed of a CD228-directed antibody and 4-1BB-directed Anticalin® proteins



A CD228-directed antibody

Directed to CD228

Key Attributes

- Fully human IgG4 monoclonal antibody
- Designed to eliminate effector functions (CDC, ADCC, and ADCP)
- Costimulatory bispecific molecule designed to deliver CD228-conditional 4-1BB costimulation to intratumoral cytotoxic T cells

4-1BB-directed Anticalin® proteins

Genetically fused to the antibody backbone and drives the clustering of 4-1BB

Targets: CD228 and 4-1BB

- CD228 is a tumor-associated antigen selectively expressed by multiple tumor types, such as mesothelioma, melanoma, and lung, pancreatic, and colorectal cancers, with minimal expression in normal tissue.[1,2]
- 4-1BB (CD137) is an inducible costimulatory immune receptor expressed on activated T cells and other immune cell populations.[3,4]

Proposed Mechanism of Action[1,a]

- T-cell-mediated cytotoxicity via costimulation of TCR signaling

ADCC: antibody-dependent cellular cytotoxicity; **ADCP**: antibody-dependent cellular phagocytosis; **CD**: cluster of differentiation; **CDC**: complement-dependent cytotoxicity; **IgG4**: immunoglobulin G4; **TCR**: T-cell receptor

[a]Based on preclinical data

1. Updegraff B. SITC virtual 2022: Poster 1201. 2. Sandall SL. Cancer Res. 2019: Abstract 2688. 3. Bartkowiak T. Front Oncol 5. 2015: 117. 4. Vinay DS. Mol Cancer Ther. 2012: 1062-70.

The safety and efficacy of this agent(s), or use in this setting, has not been established or is subject to confirmation. For an agent(s) whose safety and efficacy has not been established or confirmed, future regulatory approval or commercial availability is not guaranteed.

SGN-BB228

Proposed Mechanism of Action[1,a]

1. Binds to CD228
2. Directs clustering of 4-1BB on tumor-reactive T cells
3. Clustering of 4-1BB leads to a costimulatory signal
4. A costimulatory signal combines with a primary TCR signal and amplifies T-cell killing in CD228-expressing tumor cells



CD: cluster of differentiation; **MHC**: major histocompatibility complex; **TCR**: T-cell receptor

[a]Based on preclinical data

1. Updegraff B et al. SITC virtual 2022: Poster 1201.

Clinical Trials

Phase 1 | Phase 2 | Phase 3

RECRUITING — **SGNBB228-001: Advanced melanoma and other solid tumors** (NCT05571839) SGN-BB228

Clinical trial information retrieved from clinicaltrials.gov, accessed Oct 2023.

The safety and efficacy of this agent(s), or use in this setting, has not been established or is subject to confirmation. For an agent(s) whose safety and efficacy has not been established or confirmed, future regulatory approval or commercial availability is not guaranteed.

Printed in the USA USM/BB228/2023/0006

For more information, contact us at:
+1-855-4SEAGEN (+1-855-473-2436)
medinfo@seagen.com / medinfoEU@seagen.com
www.seagenmedinfo.com